<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04907149</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG3970-CL-107</org_study_id>
    <secondary_id>2021-000711-23</secondary_id>
    <nct_id>NCT04907149</nct_id>
  </id_info>
  <brief_title>Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970</brief_title>
  <official_title>A Phase 1, Open-label Study to Investigate the Pharmacokinetics and Metabolism of GLPG3970 in Healthy Male Subjects Following a Single Oral Dose of GLPG3970 Relative to an Intravenous [14C]GLPG3970 Microtracer and Single Oral [14C]GLPG3970 Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study in healthy male volunteers to assess how the radiolabelled test medicine is taken up&#xD;
      and broken down by the body when given by short infusion into a vein and when given by the&#xD;
      mouth in the form of a tablet and an oral solution.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2021</start_date>
  <completion_date type="Actual">July 12, 2021</completion_date>
  <primary_completion_date type="Actual">July 12, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute oral bioavailability (F [%]) of GLPG3970</measure>
    <time_frame>From Day 1 pre-dose until Day 4 in Period 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recovery of total radioactivity excreted in urine expressed as a percentage of the administered dose (Ae%).</measure>
    <time_frame>From Day 1 pre-dose until Day 8 in Period 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recovery of total radioactivity excreted in feces expressed as a percentage of the administered dose (Ae%).</measure>
    <time_frame>From Day 1 pre-dose until Day 8 in Period 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuations.</measure>
    <time_frame>From Day 1 through study completion, an average of 1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Absolute Bioavailability - Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GLPG3970 under fasted conditions followed by an intravenous (i.v.) microtracer microdose of [14C]GLPG3970 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mass Balance - Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive [14C]GLPG397 under fasted conditions on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3970 film-coated tablet</intervention_name>
    <description>Participants will receive a single oral dose of GLPG3970.</description>
    <arm_group_label>Absolute Bioavailability - Period 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]GLPG3970 solution for infusion</intervention_name>
    <description>Participants will receive an i.v. microtracer microdose.</description>
    <arm_group_label>Absolute Bioavailability - Period 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14]GLPG3970 oral solution</intervention_name>
    <description>Participants will receive a single oral dose [14C]GLPG3970.</description>
    <arm_group_label>Mass Balance - Period 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male between 30 and 64 years of age (extremes included), on the date of signing the&#xD;
             informed consent form (ICF).&#xD;
&#xD;
          -  A body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive.&#xD;
&#xD;
          -  Having a regular (at least) daily defecation pattern (i.e. 1 to 3 times per day).&#xD;
&#xD;
        This list only contains the key inclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has participated in a [14C]radiolabeled study within the past 12 months.&#xD;
&#xD;
          -  Radiation exposure, including that from the present study, excluding background&#xD;
             radiation but including diagnostic X-rays and other medical exposures, exceeding 5 mSv&#xD;
             in the last 12 month or 10 mSv in the last 5 years. Occupationally exposed worker, as&#xD;
             defined in the Ionising Radiation Regulations 2017 (UK, 2017), cannot participate in&#xD;
             the study.&#xD;
&#xD;
        This list only contains the key exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ekaterina Tankisheva</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Sciences Ltd</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

